Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.6720
-0.0180 (-2.61%)
Aug 18, 2026, 11:08 AM EDT - Market open
Aprea Therapeutics Employees
Aprea Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$648
Profits / Employee
-$1,538,408
Market Cap
8.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - |
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | -2 | -22.22% |
| Dec 31, 2022 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Lisata Therapeutics | 21 |
| Imunon | 20 |
| Soligenix | 14 |
| BioVie | 13 |
| CNS Pharmaceuticals | 8 |
| MetaVia | 8 |
| Immuron | 7 |
| Traws Pharma | 7 |
APRE News
- 1 day ago - Aprea Therapeutics reports Q2 EPS (7c), consensus (22c) - TheFly
- 6 days ago - Aprea Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewsWire
- 6 days ago - Aprea Therapeutics Earnings release: Q2 2026 - Filings
- 6 days ago - Aprea Therapeutics Quarterly report: Q2 2026 - Filings
- 6 days ago - Aprea Therapeutics Slides: Corporate presentation - Filings
- 19 days ago - Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors - GlobeNewsWire